BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

Menarini Group, Stemline, and VisualDx Join Forces to Boost Early Detection of BPDCN Using AI-Driven Skin Imaging

BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 ...

March 21, 2025 | News

Telix Secures FDA Approval for Gozellix® to Expand PSMA-PET Imaging Access in Prostate Cancer

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administrat...

March 21, 2025 | News

Formosa Pharmaceuticals and Cipla Sign Multi-Regional Licensing Deal for Ophthalmic Suspension APP13007

Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clob...

March 19, 2025 | News

SOPHiA GENETICS Surpasses Two Million Genomic Profiles Analyzed on AI-Powered Platform

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million...

March 19, 2025 | News

Akeso’s Penpulimab Secures NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National ...

March 18, 2025 | News

Rona Therapeutics Secures FDA IND Clearance for RN0361, Advancing RNAi Therapy for Severe Hypertriglyceridemia

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Dru...

March 18, 2025 | News

Innovent’s SYCUME® Becomes China’s First IGF-1R Antibody Approved for Thyroid Eye Disease

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

March 17, 2025 | News

Exicure Secures Australian Patent for Dual-Target Cancer Therapy Approach

Exicure, Inc. announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." ...

March 14, 2025 | News

Qureight and Remedy Cell Partner to Validate RC-0315’s Regenerative Potential in Idiopathic Pulmonary Fibrosis

Qureight Ltd, a Core Imaging Laboratory with deep-learning analytics, and Remedy Cell, a clinical-stage biopharmaceutical company focused on the developmen...

March 12, 2025 | News

Ascletis’ ASC47 Shows Promise as a Long-Acting, Muscle-Preserving Obesity Treatment in Phase Ib Study

ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and ...

March 12, 2025 | News

AstraZeneca’s Vision for Chronic Kidney Disease: Sylvia Varela on Transforming CKD Care in Asia

Chronic kidney disease (CKD) is a growing public health challenge in Asia, affecting over 400 million people. In an insightful discussion with BioPharma AP...

March 12, 2025 | News

Japan Grants Orphan Drug Designation to Lundbeck’s Amlenetug for Multiple System Atrophy

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetu...

March 11, 2025 | News

Gan & Lee Initiates Phase 2 Trial of Bofanglutide, the First GLP-1 Mono-Agonist to Challenge Tirzepatide in Weight Management

Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a P...

March 11, 2025 | News

Docquity Partners with RSUD Umar Wirahadikusumah Sumedang to Enhance Healthcare with AI-Powered Medical Resource Platform Dx

Dx, Docquity's AI platform which is in ongoing development, will enable physicians at the Sumedang hospital to securely access the latest medical re...

March 07, 2025 | News

Stay Connected